Announced details
Physician-initiated clinical trial for idiopathic osteonecrosis of the femoral head in patients at high risk of femoral head collapse
We will participate as a participating research institution in the joint research with Gifu University Hospital.
Gifu University Hospital is a medical institution where Akiyama Haruhiko (秋山治彦) serves as hospital director and professor of orthopaedic surgery. AMED is the Japan Agency for Medical Research and Development. Other information on location, capital and year of establishment is Not disclosed.
Japan Agency for Medical Research and Development (AMED)
Specific information, including any statement that the impact on financial results will be minor, is Not disclosed.
The company does not address Contract Value / Offering price.
AMED website (https://www.amed.go.jp/koubo/03001/02/C_00009.html) / Ministry of Health, Labour and Welfare (stating that idiopathic osteonecrosis of the femoral head is a designated intractable disease)
| Item | Details |
|---|---|
| Names of Products / Services Covered | HGF therapeutic drug (oremepermin alfa, recombinant human HGF protein) |
| Counterparty | Gifu University Hospital (principal investigator: Akiyama Haruhiko (秋山治彦)) / Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | Gifu University Hospital is a medical institution where Akiyama Haruhiko (秋山治彦) serves as hospital director and professor of orthopaedic surgery. AMED is the Japan Agency for Medical Research and Development. Other information on location, capital and year of establishment is Not disclosed. |
| Relationship with the Company | We will participate as a participating research institution in the joint research with Gifu University Hospital. |
| Launch date | Although we aim for an early start to the clinical trial, the specific start date is Not disclosed. |
| Applicable area | Physician-initiated clinical trial for idiopathic osteonecrosis of the femoral head in patients at high risk of femoral head collapse |
| Awarding / certifying body | Japan Agency for Medical Research and Development (AMED) |
| Impact on Business Performance | Specific information, including any statement that the impact on financial results will be minor, is Not disclosed. |
| Source | AMED website (https://www.amed.go.jp/koubo/03001/02/C_00009.html) / Ministry of Health, Labour and Welfare (stating that idiopathic osteonecrosis of the femoral head is a designated intractable disease) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The selection for the AMED program will enable us to obtain nonclinical trial data and other information required to conduct the clinical trial, accelerate preparations, and aim for an early start to the clinical trial.